natgillin/translations-raw huggingface dataset:
The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. 
Celotna terapevtska koncentracija insulina (insulina glargin in njegovih presnovkov) je bila pri sladkornih bolnikih tipa 1 bistveno manjša od koncentracije, potrebne za polovično največjo zasedenost receptorjev za IGF-1 in posledično aktivacijo mitogeno-proliferacijske poti, ki jo sproža receptor za IGF-1.
IGlar: Insulin glargine 100 units/ml a mITT: Modified intention-to-treat b Treatment difference: Toujeo- insulin glargine 100 units/ml; [95% Confidence Interval] c Change from baseline to Month 6 (observed case) d Change from baseline to Last main 6-month on-treatment value 
IGlar: Insulin glargin 100 enot/ml a mZNZ: modificirano z-namenom-zdravljenja b Razlika med zdravljenjema: Toujeo - insulin glargin 100 enot/ml; [95 % interval zaupanja] c Sprememba od izhodišča do 6 meseca (opazovani primeri) d Sprememba od izhodišča do zadnje glavne vrednosti med 6 meseci zdravljenja
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. 
Če urejenost glukoze ni zadostna ali obstaja nagnjenost k hiper- ali hipoglikemijam, je treba pred spreminjanjem odmerka preveriti bolnikovo upoštevanje predpisane sheme zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
Over the course of this 6-year study, 42% of the insulin glargine 100 units/ml group did not experience any hypoglycaemia. 
Med to 6-letno študijo 42 % preiskovancev v skupini z insulinom glargin 100 enot/ml ni imelo nobene hipoglikemije.
B Turn the dose selector until the dose pointer lines up with your dose. 
B Zavrtite izbirnik odmerka, dokler kazalnik odmerka ni uravnan z vašim odmerkom.
The prolonged effect of insulin glargine may delay recovery from hypoglycaemia. 
Podaljšani učinek insulina glargin lahko upočasni okrevanje po hipoglikemiji.
• You can clean the outside of your pen by wiping it with a damp cloth. 
• Zunanjost peresnika lahko očistite tako, da ga obrišete z vlažno krpo.
This medicine contains less than 1 mmol (23 mg) sodium per dose. 
Pomembne informacije o nekaterih sestavinah zdravila Toujeo To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek.
Severe allergic reactions (rare, may affect up to 1 in 1,000 people).The signs may include rash and itching all over the body, swelling of skin or mouth, shortness of breath, feeling faint (a fall in blood pressure) with fast heart beat and sweating. 
Hude alergijske reakcije (redke, pojavijo se lahko pri največ 1 od 1.000 oseb) - med znaki so lahko izpuščaj in srbenje po vsem telesu, oteklost kože ali ust, kratka sapa, omedlevica (padec krvnega tlaka) s hitrim bitjem srca in znojenjem.
• The active substance is insulin glargine. 
• Učinkovina je insulin glargin.
Clinical study safety data are not available for children under 6 years. 
Za otroke, mlajše od 6 let, podatkov o varnosti iz kliničnih študij ni.
Injection sites must be rotated within a given injection area from one injection to the next (see section 4.8). 
Mesto injiciranja na posameznem predelu je treba od injekcije do injekcije krožno menjati (glejte poglavje 4.8).
If the pen is new, you must perform safety tests before you use the pen for the first time until you see insulin coming out of the needle tip. 
Če je peresnik nov, morate varnostni preizkus opraviti, preden peresnik prvič uporabite, in sicer dokler ne vidite, da je iz konice igle prišel insulin.
26 weeks of treatment 
d 6-mesečno obdobje zdravljenja
These include patients: - in whom glycaemic control is markedly improved, - in whom hypoglycaemia develops gradually, - who are elderly, - after transfer from animal insulin to human insulin, - in whom an autonomic neuropathy is present, - with a long history of diabetes, - suffering from a psychiatric illness, - receiving concurrent treatment with certain other medicinal products (see section 4.5). 
Med takšne spadajo bolniki, ki: - se jim urejenost glikemije občutno izboljša, - se jim hipoglikemija razvije počasi, - so starejši, - so po prehodu z živalskih na humana insulinska zdravila, - imajo avtonomno nevropatijo, - so z dolgo anamnezo sladkorne bolezni, - imajo kakšno psihiatrično bolezen, - sočasno prejemajo določena druga zdravila (glejte poglavje 4.5).
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before using Toujeo. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom, preden uporabite zdravilo Toujeo.
Figure 1: Activity profile at steady state in patients with type 1 diabetes in a 36-hour euglycaemic clamp study 
Slika 1: Profil aktivnost v stanju dinamičnega ravnovesja pri bolnikih s sladkorno boleznijo tipa 1 v 36-urni študiji evglikemične uklenjenosti.
If you do not perform the safety test before each injection, you may get too little insulin. 
Če pred vsakim injiciranjem ne izvedete varnostnega preizkusa, se lahko zgodi, da injicirate premajhen odmerek insulina.
Toujeo must not be used in insulin infusion pumps. 
Zdravila Toujeo se ne sme uporabljati v infuzijskih črpalkah za insulin.
• Skin and allergic reactions at the injection site: The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation. 
• Kožne in alergijske reakcije na mestu injiciranja - med znaki so lahko pordelost, nenavadno močna bolečina med injiciranjem, srbenje, urtikarija, otekanje ali vnetje.
Insulin glargine 100 units/ml did not alter the relative risk for CV disease and CV mortality when compared to standard of care. 
Insulin glargin 100 enot/ml v primerjavi s standardno oskrbo ni spremenil relativega tveganja za KV bolezen ali KV umrljivost.
Re-use of needles increases the risk of blocked needles which may cause underdosing or overdosing (see section 4.4 and 6.6). 
Ponovna uporaba igel poveča tveganje za zamašitev, to pa lahko povzroči premajhno ali preveliko odmerjanja (glejte poglavji 4.4 in 6.6).
EU/1/00/133/033 1 pen (SoloStar) EU/1/00/133/034 3 pens (SoloStar) EU/1/00/133/035 5 pens (SoloStar) EU/1/00/133/036 10 pens (SoloStar) EU/1/00/133/037 1 pen (DoubleStar) EU/1/00/133/038 3 pens (DoubleStar) EU/1/00/133/041 10 pens (DoubleStar) 
EU/1/00/133/033 1 injekcijski peresnik (SoloStar) EU/1/00/133/034 3 injekcijski peresniki (SoloStar) EU/1/00/133/035 5 injekcijskih peresnikov (SoloStar) EU/1/00/133/036 10 injekcijskih peresnikov (SoloStar) EU/1/00/133/037 1 injekcijski peresnik (DoubleStar) EU/1/00/133/038 3 injekcijski peresniki (DoubleStar) EU/1/00/133/041 10 injekcijskih peresnikov (DoubleStar)
If you use a new pen, perform a safety test (see STEP 3). 
Če uporabite nov peresnik, izvedite varnostni preizkus (3.
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper-or hypoglycaemia. 
V redkih primerih je zaradi prisotnosti takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper- ali hipoglikemiji.
In type 1 diabetes mellitus, Toujeo must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements. 
Pri sladkorni bolezni tipa 1 je treba zdravilo Toujeo uporabljati v kombinaciji s kratko-/hitrodelujočim insulinom za kritje potreb po insulinu ob obrokih.
Instead, regular insulin administered intravenously is recommended in such cases. 
V takšnih primerih je treba intravensko uporabiti običajni insulin.
To prevent the possible transmission of disease, insulin pens should never be used for more than one person, even when the needle is changed. 
Da bi preprečili možen prenos bolezni, se insulinski peresniki nikoli ne smejo uporabljati pri več kot eni osebi, tudi če se zamenja injekcijska igla.
• You change the area of skin where you inject insulin. 
• Zamenjate predel kože, kamor injicirate insulin, npr. s stegna na nadlaket.
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine 100 units/ml and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine 100 units/ml and 2.44 for standard care group. 
Deleža hudih hipoglikemij (prizadeti preiskovanci na 100 preiskovanec-let izpostavljenosti) sta bila 1,05 za insulin glargin 100 enot/ml in 0,30 za standardno oskrbo, deleža potrjenih ne-hudih hipoglikemij pa sta bila 7,17 za insulin glargin in 7,71 za standardno oskrbo.
If you do, it could lead to very high blood sugar and a build-up of acid in the blood (ketoacidosis). 
Če ga prenehate uporabljati, se vam lahko krvni sladkor zelo zviša in v krvi se lahko kopiči kislina (ketoacidoza).
Toujeo contains 3 times more insulin in 1 ml than standard insulin, which contains 100 unit/ml. 
Zdravilo Toujeo vsebuje v 1 ml 3-krat več insulina kot standardni insulin: standardni insulin vsebuje 100 enot/ml.
The safety and efficacy of Toujeo in children below 6 years of age have not been established. 
Varnost in učinkovitost zdravila Toujeo pri otrocih, mlajših od 6 let, nista bili ugotovljeni.
Effects of insulin glargine 100 units/ml (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. 
Učinke insulina glargin 100 enot/ml (enkrat na dan) na diabetično retinopatijo so raziskali v odprti, petletni, z NPH kontrolirani študiji (NPH uporabljan dvakrat na dan) pri 1.024 bolnikih s sladkorno boleznijo tipa 2; napredovanje retinopatije za 3 ali več stopenj po lestvici ETDRS (Early Treatment Diabetic Retinopathy Study) so v študiji preiskovali s slikanjem očesnega ozadja.
However, only very rarely, this will require a change to your insulin dose. 
V redkih primerih to zahteva spremembo odmerka insulina.
To avoid dosing errors and potential overdose, the patients must be instructed to never use a syringe to remove Toujeo (insulin glargine 300 units/ml) from the Toujeo SoloStar pre-filled pen or Toujeo DoubleStar pre-filled pen (see section 4.9 and 6.6). 
Za preprečitev napak pri odmerjanju in možnega prevelikega odmerjanja je treba bolnikom naročiti, naj nikdar z brizgo ne jemljejo zdravila Toujeo (insulin glargin 300 enot/ml) iz napolnjenega injekcijskega peresnika Toujeo SoloStar ali napolnjenega injekcijskega peresnika Toujeo DoubleStar (glejte poglavji 4.9 in 6.6).
• Your pen contains a total of 450 units of insulin. 
• Vaš peresnik vsebuje vsega skupaj 450 enot insulina.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include anti-hyperglycaemic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. 
Med zdravili, ki lahko povečajo učinek znižanja glukoze v krvi in povečajo nagnjenost k hipoglikemiji, so antihiperglikemična zdravila, zaviralci angiotenzinske konvertaze (ACE), dizopiramid, fibrati, fluoksetin, zaviralci monoaminooksidaze (MAO), pentoksifilin, propoksifen, salicilati in sulfonamidni antibiotiki.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. 
Opisani so bili primeri srčnega popuščanja med uporabo pioglitazona skupaj z insulinom, zlasti pri bolnikih z dejavniki tveganja za srčno popuščanje.
In a clinical pharmacology study, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. 
Klinična farmakološka študija je pokazala, da sta intravensko uporabljeni insulin glargin in humani insulin v enakih odmerkih ekvipotentna.
including in Toujeo therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway. 
Vendar so terapevtske koncentracije med insulinskim zdravljenjem, vključno z zdravljenjem z zdravilom Toujeo, bistveno manjše kot farmakološke koncentracije, potrebne za aktivacijo poti IGF-1.
EU/1/00/133/039 6 pens (2 packs of 3) EU/1/00/133/040 9 pens (3 packs of 3) 
EU/1/00/133/039 6 injekcijskih peresnikov (2 pakiranji po 3) EU/1/00/133/040 9 injekcijskih peresnikov (3 pakiranja po 3)
At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine 100 units/ml group and a mean decrease of 0.8 kg in the standard care group. 
Na zadnjem obisku med zdravljenjem je bilo povprečno povečanje telesne mase od izhodišča v skupini z insulinom glargin 100 enot/ml 1,4 kg in povprečno zmanjšanje v skupini s standardno oskrbo 0,8 kg.
Switch between insulin glargine 100 units/ml and Toujeo Since insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not interchangeable, switching may result in the need for a change in dose and should only be done under strict medical supervision (see section 4.2). 
Prehod med insulinom glargin 100 enot/ml in zdravilom Toujeo Ker insulin glargin 100 enot/ml in zdravilo Toujeo nista bioekvivalentna in medsebojno zamenljiva, je ob prehodu lahko potrebna sprememba odmerka; takšen prehod se sme opraviti le pod strogim zdravniškim nadzorom (glejte poglavje 4.2).
As cutaneous amyloidosis may lead to insulin resistance due to poor absorption from the infiltrated site, health care professionals and patients should be informed of this event in the PI. Absorption of insulin could be improved by rotating the injection site. 
Ker lahko kožna amiloidoza, zaradi slabe absorpcije iz mesta infiltracije, povzroči insulinsko rezistenco, je treba zdravstvene delavce in bolnike seznaniti s tem pojavom preko informacij o zdravilu.
Toujeo contains insulin called “insulin glargine”. 
Zdravilo Toujeo vsebuje insulin, ki se imenuje “insulin glargin”.
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes with a medicinal product containing insulin glargine 100 units/ml) indicate no specific adverse effects on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. 
Velika količina podatkov o nosečnicah (več kot 1000 izidov nosečnosti z zdravilom, ki vsebuje insulin glargin 100 enot/ml ) ne kaže specifičnih neželenih učinkov insulina glargin na nosečnost; prav tako ne kaže, da bi insulin glargin povzročal specifične malformacije, fetotoksične učinke ali toksične učinke na novorojenčka.
• Your pen contains a total of 900 units of insulin. 
• Vaš peresnik vsebuje vsega skupaj 900 enot insulina.
• You are taking or have stopped taking certain other medicines (see section 2, "Other medicines and Toujeo"). 
• Jemljete ali ste nehali jemati določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo Toujeo ").
Breast-feeding women may require adjustments in insulin dose and diet. 
Nosečnice lahko potrebujejo prilagoditev odmerka insulina in prehrane.
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin. 
Zaviralci adrenergičnih receptorjev beta, klonidin, litijeve soli in alkohol lahko vpliv insulina na znižanje glukoze v krvi povečajo ali zmanjšajo.
Mixing or diluting Toujeo changes its time/action profile and mixing causes precipitation. 
Mešanje ali redčenje zdravila Toujeo spremeni časovni potek delovanja; mešanje lahko povzroči precipitacijo.
With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. 
Zaradi boljše urejenosti presnove in večje občutljivosti za insulin je lahko potrebna nadaljnja prilagoditev odmerka.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. 
Med zdravili oz. učinkovinami, ki lahko zmanjšajo učinek znižanja glukoze v krvi, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestageni, derivati fenotiazina, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, atipična antipsihotična zdravila (npr. klozapin in olanzapin) in zaviralci proteaz.
Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 
Zdravljenje sladkorne bolezni pri odraslih, mladostnikih in otrocih od 6. leta starosti naprej.
See “Pioglitazone used together with insulin”. 
• Pioglitazon - Glejte "Uporaba pioglitazona skupaj z insulinom".
The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomized, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus (treated with ≤1 antidiabetic oral agent) (88% of participants). 
Študija zmanjšanja izidov z uvodno uporabo glargin (ORIGIN - Outcome Reduction with Initial Glargine INtervention) je bila multicentrična, randomizirana študija s faktorskim načrtom 2 x 2, v katero je bilo vključenih 12.537 sodelujočih z velikim kardiovaskularnim (KV) tveganjem in moteno glukozo na tešče (MGT) ali moteno toleranco za glukozo (MTG) (12 % sodelujočih), ali s sladkorno boleznijo tipa 2, zdravljeno z ≤ 1 peroralnim antidiabetikom (88 % sodelujočih).
Prior to launch of Toujeo 300 units/ml in each Member State the MAH must agree the content and format of the educational programme, including communication media, distribution modalities, and any other aspects, with the National Competent Authority. 
Pred prihodom zdravila Toujeo 300 enot/ml na trg v posamezni državi članici mora imetnik dovoljenja za promet z zdravilom (MAH) s pristojnim nacionalnim organom uskladiti vsebino in obliko izobraževalnega programa, vključno s sredstvi obveščanja, načinom razdeljevanja in morebitnimi drugimi vidiki.
Overall the incidence of hypoglycaemia in patients in any category was similar in both treatment groups, with 97.9% of patients in the Toujeo group and 98.2% in the insulin glargine 100 units/mL group reporting at least one event. 
V celoti je bila pojavnost hipoglikemij pri bolnikih v vseh kategorijah v obeh terapevtskih skupinah podobna; o vsaj enem pojavu je poročalo 97,9 % bolnikov v skupini z zdravilom Toujeo in 98,2 % bolnikov v skupini z insulinom glarginom 100 enot/ml.
The more sustained release of insulin glargine from the Toujeo precipitate compared to insulin glargine 100 units/ml is attributable to the reduction of the injection volume by two thirds that results in a smaller precipitate surface area. 
Podaljšano sproščanje insulina glargin iz precipitata zdravila Toujeo v primerjavi z insulinom glargin 100 enot/ml je mogoče pripisati zmanjšanju injicirane količine za dve tretjini: posledica tega je manjša površina precipitata.
Only use needles that are compatible for use with Toujeo (e.g. needles from BD, Ypsomed, Artsana or Owen Mumford). 
Uporabljajte samo igle, ki primerne za uporabo z zdravilom Toujeo (npr. igle izdelovalcev BD, Ypsomed, Artsana ali Owen Mumford).
Participants were randomized (1:1) to receive insulin glargine 100 units/ml (n=6264), titrated to reach FPG ≤95 mg/dl (5.3 mM), or standard care (n=6273). 
Preiskovance so v razmerju 1:1 randomizirali na prejemanje insulina glargin 100 enot/ml (n = 6264), titriranega tako, da je bila dosežena glukoza v plazmi na tešče ≤ 95 mg/dl (5,3 mM), ali na standardno oskrbo (n = 6273).
In the event of blocked needle, the patients must follow the instructions described in Step 3 of the Instructions for Use accompanying the package leaflet (see section 4.2 and 4.4). 
Če je igla zamašena, mora bolnik slediti navodilom, opisanim v 3. koraku navodila za uporabo, ki je priložen navodilu za uporabo (glejte poglavji 4.2 in 4.4).
The prolonged duration of action of Toujeo is dependent on its injection into subcutaneous tissue. 
Podaljšano delovanje zdravila Toujeo je odvisno od tega, da je zdravilo injicirano v podkožno tkivo.
• Detailed description of the modalities used for the self-administration of insulin glargine: - That insulin glargine 100 units/ml and insulin glargine 300 units/ml (Toujeo SoloStar and Toujeo 
• Podroben opis načinov za samoinjiciranje insulina glargin: - Insulin glargin 100 enot/ml in insulin glargin 300 enot/ml (zdravilo Toujeo SoloStar in zdravilo
Mean change in body weight of less than 1 kg at the end of the 6-month period was observed in Toujeo-treated patients (see Table 1 and 2). 
Pri bolnikih, ki so prejemali zdravilo Toujeo, so na koncu 6-mesečnega obdobja ugotovili povprečno spremembo telesne mase za manj kot 1 kg (glejte preglednici 1 in 2).
If you see insulin coming out of the needle tip, the pen is ready to use. 
Če vidite, da je iz konice igle prišel insulin, je peresnik pripravljen za uporabo.
Taking into account the PRAC Assessment Report on the PSUR(s) for insulin glargine, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za insulin glargin je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
The superiority of Toujeo over insulin glargine 100 units/ml in lowering the risk of confirmed nocturnal hypoglycaemia was shown in patients with type 2 diabetes treated with basal insulin in combination with either non-insulin anti-hyperglycaemic medicinal product (18% risk reduction) or mealtime insulin (21% risk reduction) during the period from week 9 to end of study period. 
Superiornost zdravila Toujeo nad insulinom glargin 100 enot/ml za znižanje tveganja za potrjene hipoglikemije so dokazali pri bolnikih s sladkorno boleznijo tipa 2, ki so prejemali bazalni insulin v kombinaciji ali z neinsulinskimi antihiperglikemičnimi zdravili (18 % zmanjšanje tveganja) ali insulinom ob obrokih (21 % zmanjšanje tveganja) v obdobju od 9. tedna do konca obdobja študije.
Only use needles that are compatible for use with Toujeo DoubleStar (e.g. needles from BD, Ypsomed, Artsana or Owen Mumford) that are 8 mm long or shorter. 
Uporabljajte samo igle, ki primerne za uporabo z zdravilom Toujeo DoubleStar (npr. igle izdelovalcev BD, Ypsomed, Artsana ali Owen Mumford) in niso daljše od 8 mm.
A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine. 
Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka insulina glargin.
Rarely, insulin may cause oedema particularly if previously poor metabolic control is improved by intensified insulin therapy. 
Redko lahko insulin povzroči edeme, še zlasti, če intenzivirano insulinsko zdravljenje izboljša presnovno urejenost, ki je bila prej slaba.
- Switching from once-daily basal insulins to once-daily Toujeo can be done unit-to-unit based on the previous basal insulin dose. 
- Prehod z bazalnih insulinov enkrat na dan na zdravilo Toujeo enkrat na dan je mogoče izvesti na podlagi enote-za-enoto predhodno uporabljanega odmerka bazalnega insulina.
Switch between other insulins and Toujeo 
Prehod med drugimi insulini in zdravilom Toujeo
Hypoglycaemia (low blood sugar levels) 
Hipoglikemija (nizka koncentracija krvnega sladkorja)
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism (see section 4.8). 
Bolnikom z okvaro ledvic se lahko potreba po insulinu zmanjša zaradi zmanjšane presnove insulina (glejte poglavje 4.8).